You are viewing the site in preview mode

Skip to main content


Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study

Fig. 1

Antiretrovirals included in first-line cART regimen: HIV Centre Belgrade, Serbia and Royal Free Hospital, UK. Antiretrovirals included in first line cART at the HIV Centre Belgrade, Serbia (n = 597; a and c) and at the Royal Free Hospital, London, UK (n = 1763; b and d). Choice divided according to nucleoside reverse transcriptase inhibitor (NRTI) backbone prescribed (a and b) and according to the ‘third’ drug (c and d) prescribed. AZT – zidovudine, 3TC – lamivudine, ABC – abacavir, FTC – emtricitabine, TDF – tenofovir, ddI – didanosine, d4T – stavudine, NRTI - non-nucleoside reverse transcriptase inhibitor, NNRTI - non-nucleoside reverse transcriptase inhibitor, LPV/r – lopinavir/ritonavir, PI/r – protease inhibitor boosted with ritonavir, cART = combination antiretroviral therapy

Back to article page